Recce Pharmaceuticals provides new hope in fight against superbugs

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham speaks with Proactive after welcoming positive clinical responses to a new gel formulation of its R327® drug candidate, covered by the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS). Anecdotal results from two patient case studies are a positive indicator of the gel formulation’s therapeutic potential, while results from an ex vivo burn wound study indicate the R327 gel had the greatest overall efficacy against a strand of antibiotic-resistant bacteria. Recce is now advancing clinical trial applications to evaluate the R327 gel’s efficacy in common and complicated skin and soft tissue infections in the lab.